The Appy Files, Episode 2: To PIPAC or Not to PIPAC?

Episode 2 of The Appy Files, ACPMP’s podcast bringing together expert insights and community connection to explore the latest in appendix cancer research, is now available. The podcast is hosted by ACPMP Patient Liaison Shannon Altpeter, DMSc, PA-C, a surgical oncology physician assistant at Allegheny Health Network.

Episode 2: To PIPAC or Not to PIPAC?

In this episode, Shannon sits down with Dr. Mustafa Raoof, surgical oncologist and physician scientist at City of Hope, for a candid conversation about PIPAC (pressurized intraperitoneal aerosol chemotherapy) and his new IMPACT clinical trial.

Dr. Raoof breaks down how PIPAC differs from HIPEC, what early studies show, and why he believes it belongs in clinical trials for now. He also walks through who may qualify for IMPACT and what patients should weigh before pursuing PIPAC.

Stay to the end to find out what Dr. Raoof would do once cancer is cured. (Hint: it involves a guitar.)

Listen to Episode 2 on Spotify

About the IMPACT trial

IMPACT is a Phase 3 clinical trial sponsored by City of Hope. It compares PIPAC with mitomycin to standard chemotherapy (FOLFIRI plus bevacizumab) for patients with appendix or colorectal cancer that has spread to the lining of the abdomen (peritoneum) and cannot be removed with surgery.

To learn more about eligibility, study locations, and how to get in touch with the study team, view the IMPACT trial (NCT07271355) on ClinicalTrials.gov. The IMPACT trial is also listed in ACPMP’s Clinical Trials database. If you are interested in a clinical trial, talk with your care team about whether it may be a good fit for you.

More on PIPAC and clinical trials

How to listen

Listen and follow The Appy Files on Spotify. Follow the podcast to stay up to date on new episodes, and if you enjoy listening, please leave a rating and review.

Want to know when new episodes are released? Join the ACPMP mailing list.